- Bayer expects 2025 Group sales of €46-48B and EBITDA of €9.7-10.2B.
- Q2 2025 sales reached €10.7B, with Crop Science sales up 2.2%.
- Bayer allocated €1.2B for Roundup litigation, settling 131,000 claims.
- Bayer anticipates special items in EBITDA to be -€3.5 to -€2.5B for 2025.
Financial Update
Bayer has revised its 2025 financial guidance, projecting Group sales of €46 to €48 billion and EBITDA before special items of €9.7 to €10.2 billion. The company expects core earnings per share to be between €4.80 and €5.30. Currency effects are anticipated to reduce Group sales by €2 billion and EBITDA by €500 million, while positively impacting net financial debt by €1.2 billion.
Q2 2025 Performance
In the second quarter of 2025, Bayer reported Group sales of approximately €10.7 billion. Crop Science sales increased by 2.2% on a currency- and portfolio-adjusted basis, while Pharmaceuticals and Consumer Health divisions saw marginal sales growth. Group EBITDA before special items was around €2.1 billion, with divisional EBITDA at €0.7 billion for Crop Science, €1.1 billion for Pharmaceuticals, and €0.3 billion for Consumer Health.
Litigation and Provisions
Bayer has set aside €1.2 billion for Roundup litigation, part of a total €1.7 billion provision for US legal issues. The company has settled 131,000 of 192,000 glyphosate claims, reducing unresolved claims to 61,000. Additional provisions of €530 million were recorded for PCB-related cases, including the Burke case and potential settlements related to the Sky Valley Education Center.
Special Items and Future Outlook
Special items in EBIT for Q2 totaled approximately -€1 billion, mainly due to impairment loss reversals and litigation provisions. For the full year, Bayer expects special items in EBITDA to range from -€3.5 to -€2.5 billion. The company continues to monitor geopolitical developments and their financial impacts.
